Riskpilot← Back to searchSign inGet full accessBK Laboratorieutveckling AB
ABActiveOrg 5592887102Sandsjön 700Business and other management consultancy activities · NACE 7020Est. 20201 employees
Revenue 2025
SEK 2,3M
+11% vs 2024
EBITDA margin
54.5%
+25% vs 2024
Equity ratio
94.7%
Financial strength
Net profit 2025
SEK 1M
+17% vs 2024
| Revenue | SEK 2,3M | +11% |
| EBITDA | SEK 1,3M | +25% |
| Net profit | SEK 1M | +17% |
| Total assets | SEK 3,2M | +31% |
| Equity | SEK 3M | +37% |
| Employees | 1 | — |
Legal name
BK Laboratorieutveckling AB
Org number
5592887102
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
9 december 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företaget erbjuder tjänster utifrån mångårig erfarenhet av att leda och driva verksamhetsutveckling av funktioner och tekniker kopplade till laboratoriediagnostik. Detta sker genom att på konsultbasis stödja uppdragsgivarna att lösa sina utmaningar utifrån en kvalitet, krav eller processtyrd verksamhets- utveckling.
Address
Sandsjön 700
Email
birgitta.kallberg@labu.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 793 | 2 015 | 2 103 | 2 102 | 2 332 |
| Staff expenses | — | −892 | −1 012 | −1 045 | −991 |
| EBITDA | 615 | 1 103 | 1 069 | 1 016 | 1 272 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 615 | 1 103 | 1 069 | 1 016 | 1 272 |
| Net financials | −1 | −52 | −12 | 61 | 12 |
| Profit before tax | 615 | 1 051 | 1 057 | 1 078 | 1 284 |
| Tax | −132 | −227 | −220 | −210 | −265 |
| Net profit | 483 | 823 | 837 | 868 | 1 020 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 751 | 1 435 | 2 046 | 2 463 | 3 216 |
| Equity | 508 | 1 151 | 1 803 | 2 226 | 3 045 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 243 | 284 | 243 | 237 | 171 |
| Total debt | 243 | 284 | 243 | 237 | 171 |
EBITDA margin
54.5%
This company
15.8%
Market median
+245% vs market
20212025
Equity ratio
94.7%
This company
38.2%
Market median
+148% vs market
20212025
Return on equity
33.5%
This company
18.4%
Market median
+82% vs market
20212025
Net profit margin
43.7%
This company
8.1%
Market median
+440% vs market
20212025
Asset turnover
0.73×
This company
1.12×
Market median
-35% vs market
20212025
Debt / equity
0.06×
This company
0.62×
Market median
+90% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-12-01 – 2021-08-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BK Laboratorieutveckling AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Birgitta Elisabet Kallberg | Board of Directors | 0 companies |
| John Peter Johnsson | Deputy Board Member | 0 companies |